In silico discovery of androgen receptor antagonists with activity in castration resistant prostate cancer

Molecular Endocrinology

Volumn 26, Issue 11, 2012, Pages 1836-1846

  Shen, Howard C ^a   Shanmugasundaram, Kumaran ^a   Simon, Nicholas I ^a   Cai, Changmeng ^a   Wang, Hongyun ^a   Chen, Sen ^a   Balk, Steven P ^a   Rigby, Alan C ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

A 36; A 61; A 89; ANDROGEN RECEPTOR; ANDROGEN RECEPTOR ANTAGONIST; ANDROSTANOLONE; ANTINEOPLASTIC AGENT; BICALUTAMIDE; CHEMOTYPE A; CHEMOTYPE B; CHEMOTYPE C; CHEMOTYPE D; CHEMOTYPE E; CHEMOTYPE F; ENZALUTAMIDE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CASTRATION RESISTANT PROSTATE CANCER; CELL PROLIFERATION; CHEMICAL STRUCTURE; CHROMATIN; CHROMATIN IMMUNOPRECIPITATION; COMPUTER MODEL; CONTROLLED STUDY; DRUG ACTIVITY; DRUG DEVELOPMENT; DRUG EFFICACY; DRUG IDENTIFICATION; DRUG STRUCTURE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LIGAND BINDING; MALE; MOLECULAR LIBRARY; MOUSE; NONHUMAN; PHARMACOPHORE; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN DOMAIN; RECEPTOR BINDING; STRUCTURAL HOMOLOGY; TUMOR CELL; TUMOR XENOGRAFT;

ANDROGEN RECEPTOR ANTAGONISTS; ANIMALS; CELL NUCLEUS; CERCOPITHECUS AETHIOPS; COMPUTATIONAL BIOLOGY; COS CELLS; DNA, NEOPLASM; DRUG DISCOVERY; HUMANS; MALE; MICE; MODELS, BIOLOGICAL; MODELS, MOLECULAR; ORCHIECTOMY; PROSTATIC NEOPLASMS; PROTEIN BINDING; PROTEIN STRUCTURE, SECONDARY; PROTEIN TRANSPORT; PROTEOLYSIS; RECEPTORS, ANDROGEN; REPRODUCIBILITY OF RESULTS; STRUCTURAL HOMOLOGY, PROTEIN; XENOGRAFT MODEL ANTITUMOR ASSAYS;

MUS;

EID: 84868089097     PISSN: 08888809     EISSN: None     Source Type: Journal    
DOI: 10.1210/me.2012-1222     Document Type: Article

References (32)

1. Attard G, Cooper CS, de Bono JS 2009 Steroid hormone receptors in prostate cancer: a hard habit to break? Cancer Cell 16:458-462
2. Attard G, Reid AH, Olmos D, de Bono JS 2009 Antitumor activity with CYP 17 blockade indicates that castration-resistant prostate cancer frequently remains hormone driven. Cancer Res 69:4937-4940
3. Joyce R, Fenton MA, Rode P, Constantine M, Gaynes L, Kolvenbag G, DeWolf W, Balk S, Taplin ME, Bubley GJ 1998 High dose bicalutamide for androgen independent prostate cancer: effect of prior hormonal therapy. J Urol 159:149-153
4. Taplin ME, Bubley GJ, Ko YJ, Small EJ, Upton M, Rajeshkumar B, Balk SP 1999 Selection for androgen receptor mutations in prostate cancers treated with androgen antagonist. Cancer Res 59:2511-2515
5. Taplin ME, Rajeshkumar B, Halabi S, Werner CP, Woda BA, Picus J, Stadler W, Hayes DF, Kantoff PW, Vogelzang NJ, Small EJ 2003 Androgen receptor mutations in androgen-independent prostate cancer: Cancer and Leukemia Group B Study 9663. J Clin Oncol 21:2673-2678
6. Tran C, Ouk S, Clegg NJ, Chen Y, Watson PA, Arora V, Wongvipat J, Smith-Jones PM, Yoo D, Kwon A, Wasielewska T, Welsbie D, Chen CD, Higano CS, Beer TM, Hung DT, Scher HI, Jung ME, Sawyers CL 2009 Development of a second-generation antiandrogen for treatment of advanced prostate cancer. Science 324:787-790
7. Jung ME, Ouk S, Yoo D, Sawyers CL, Chen C, Tran C, Wongvipat J 2010 Structure-activity relationship for thiohydantoin androgen receptor antagonists for castration-resistant prostate cancer (CRPC). J Med Chem 53:2779-2796
8. Scher HI, Beer TM, Higano CS, Anand A, Taplin ME, Efstathiou E, Rathkopf D, Shelkey J, Yu EY, Alumkal J, Hung D, Hirmand M, Seely L, Morris MJ, Danila DC, Humm J, Larson S, Fleisher M, Sawyers CL 2010 Antitumour activity of MDV 3100 in castrationresistant prostate cancer: a phase 1-2 study. Lancet 375:1437-1446
9. Masiello D, Cheng S, Bubley GJ, Lu ML, Balk SP 2002 Bicalutamide functions as an androgen receptor antagonist by assembly of a transcriptionally inactive receptor. J Biol Chem 277:26321-26326
10. Chen CD, Welsbie DS, Tran C, Baek SH, Chen R, Vessella R, Rosenfeld MG, Sawyers CL 2004 Molecular determinants of resistance to antiandrogen therapy. Nat Med 10:33-39
11. He B, Gampe Jr RT, Kole AJ, Hnat AT, Stanley TB, An G, Stewart EL, Kalman RI, Minges JT, Wilson EM 2004 Structural basis for androgen receptor interdomain and coactivator interactions suggests a transition in nuclear receptor activation function dominance. Mol Cell 16:425-438
12. Hur E, Pfaff SJ, Payne ES, Grøn H, Buehrer BM, Fletterick RJ 2004 Recognition and accommodation at the androgen receptor coactivator binding interface. PLoS Biol 2:E 274
13. Lamont KR, Tindall DJ 2010 Androgen regulation of gene expression. Adv Cancer Res 107:137-162
14. Sack JS, Kish KF, Wang C, Attar RM, Kiefer SE, An Y, Wu GY, Scheffler JE, Salvati ME, Krystek Jr SR, Weinmann R, Einspahr HM 2001 Crystallographic structures of the ligand-binding domains of the androgen receptor and its T 877A mutant complexed with the natural agonist dihydrotestosterone. Proc Natl Acad Sci USA 98:4904-4909
15. Bohl CE, Gao W, Miller DD, Bell CE, Dalton JT 2005 Structural basis for antagonism and resistance of bicalutamide in prostate cancer. Proc Natl Acad Sci USA 102:6201-6206
16. Nicholson RI, Gee JM, Bryant S, Francis AB, McClelland RA, Knowlden J, Wakeling AE, Osborne CK 1996 Pure antiestrogens. The most important advance in the endocrine therapy of breast cancer since 1896. Ann NY Acad Sci 784:325-335
17. Madauss KP, Grygielko ET, Deng SJ, Sulpizio AC, Stanley TB, Wu C, Short SA, Thompson SK, Stewart EL, Laping NJ, Williams SP, Bray JD 2007 A structural and in vitro characterization of asoprisnil: a selective progesterone receptor modulator. Mol Endocrinol 21:1066-1081
18. Kahraman A, Morris RJ, Laskowski RA, Thornton JM 2007 Shape variation in protein binding pockets and their ligands. J Mol Biol 368:283-301
19. Richmond NJ, Willett P, ClarkRD 2004 Alignment of three-dimensional molecules using an image recognition algorithm. J Mol Graph Model 23:199-209
20. Abrahamian E, Fox PC, Naerum L, Christensen IT, Thøgersen H, Clark RD 2003 Efficient generation, storage, and manipulation of fully flexible pharmacophore multiplets and their use in 3-D similarity searching. J Chem Inf Comput Sci 43:458-468
21. Jain AN 2003 Surflex: fully automatic flexible molecular docking using a molecular similarity-based search engine. J Med Chem 46: 499-511
22. Subramanian K 2005 truPK-human pharmacokinetic models for quantitative ADME prediction. Expert Opin Drug Metab Toxicol 1:555-564
23. Hodgson MC, Astapova I, Cheng S, Lee LJ, Verhoeven MC, Choi E, Balk SP, Hollenberg AN 2005 The androgen receptor recruits nuclear receptor CoRepressor (N-CoR) in the presence of mifepristone via itsNand C termini revealing a novel molecular mechanism for androgen receptor antagonists. J Biol Chem 280:6511-6519
24. Hodgson MC, Shen HC, Hollenberg AN, Balk SP 2008 Structural basis for nuclear receptor corepressor recruitment by antagonistliganded androgen receptor. Mol Cancer Ther 7:3187-3194
25. Kauppi B, Jakob C, Färnegardh M, Yang J, Ahola H, Alarcon M, Calles K, Engström O, Harlan J, Muchmore S, Ramqvist AK, Thorell S, Ohman L, Greer J, Gustafsson JA, Carlstedt-Duke J, Carlquist M 2003 The three-dimensional structures of antagonistic and agonistic forms of the glucocorticoid receptor ligand-binding domain: RU-486 induces a transconformation that leads to active antagonism. J Biol Chem 278:22748-22754
26. Frego L, Davidson W 2006 Conformational changes of the glucocorticoid receptor ligand binding domain induced by ligand and cofactor binding, and the location of cofactor binding sites determined by hydrogen/deuterium exchange mass spectrometry. Protein Sci 15:722-730
27. Shang Y, Myers M, Brown M 2002 Formation of the androgen receptor transcription complex. Mol Cell 9:601-610
28. Loberg RD, St John LN, Day LL, Neeley CK, Pienta KJ 2006 Development of the VCaP androgen-independent model of prostate cancer. Urol Oncol 24:161-168
29. Cai C, Wang H, Xu Y, Chen S, Balk SP 2009 Reactivation of androgen receptor-regulated TMPRSS 2:ERG gene expression in castration-resistant prostate cancer. Cancer Res 69:6027-6032
30. Osborne CK, Wakeling A, Nicholson RI 2004 Fulvestrant: an oestrogen receptor antagonist with a novel mechanism of action. Br J Cancer 90(Suppl 1):S 2-S 6
31. Bruno RD, Vasaitis TS, Gediya LK, Purushottamachar P, Godbole AM, Ates-Alagoz Z, Brodie AM, Njar VC 2011 Synthesis and biological evaluations of putative metabolically stable analogs of VN/ 124-1 (TOK-001): head to head anti-tumor efficacy evaluation of VN/124-1 (TOK-001) and abiraterone in LAPC-4 human prostate cancer xenograft model. Steroids 76:1268-1279
32. Narayanan R, Yepuru M, Szafran AT, Szwarc M, Bohl CE, Young NL, Miller DD, Mancini MA, Dalton JT 2010 Discovery and mechanistic characterization of a novel selective nuclear androgen receptor exporter for the treatment of prostate cancer. Cancer Res 70:842-851